To

Date: 01st November, 2026

The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 (BSE Scrip Code: 544742)	The Manager, NSE Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai- 400051. (NSE Symbol: SAIPARENT)

Dear Sir/Madam,

Unit: Sai Parenterals Limited

Sub: Statement on Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

***

Pursuant to Regulation 32 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019 this is to inform the Exchanges that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offer (IPO) of the Company during the quarter ended on 30th September, 2026. Please find enclosed herewith a statement in this regard.

This is for the information and records of the Exchanges, please.

Thanking you.

Yours faithfully,
For Sai Parenterals Limited

ANIL KUMAR KARUSALA

Digitally signed by ANIL KUMAR KARUSALA
Date: 2026.11.01 17:46:45 +05'30'

Mr. Anil Kumar Karusala
Managing Director
(DIN- 01866646)

Encl: as above

Statement of Deviation or Variation in utilization of funds raised

Name of listed entity	Sai Parenterals Limited
Mode of Fund Raising	Initial Public Offer (IPO)
Type of Instrument	Equity
Date of Raising Funds	24 March 2026 to 27 March 2026 (Anchor Issue date: 23rd March 2026)
Amount Raised	2,850 million
Report filed for Quarter ended	Quarter ended as on 30th September, 2026.
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	M/s. India Ratings & Research Private Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	NIL
Comments of the auditors, if any	NIL

Sr. No	Original Object	Modified Object, if any	Original Allocation (in Millions)	Modified allocation, if any	Funds Utilised (in Millions)	Amount of Deviation/ Variation for the quarter according to pplicable object	Remarks if any
1.	Capacity expansion and upgradation of manufacturing facilities	Not Applicable	1107.95	269.61	98.51	NA	--
2.	Capacity expansion and upgradation of manufacturing facilities	60% equity in Saicriti Pharma, to construct a new critical-care injectable facility at Gummadidala, outside the ORR	0	838.34	100	NA	
3.	Establishment of a new R&D Centre	60% equity in Prathyak Laboratories, an operating R&D centre at Genome Valley	180.23	0	150	NA	--
4.	Repayment / p-repayment- of certain outstanding borrowings	Not Applicable	143.02	0	136.54	NA	--
5.	Working capital requirements	Not Applicable	330.00	0	330.00	NA	--
6.	Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte	Not Applicable	356.41	0	356.41	NA	--

	Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia)						
7.	General Corporate Purposes	Not Applicable	447.40	0	217.57	NA	--
8.	Issue Related Expenses	Not Applicable	284.99	0	284.90	NA	--